Hiller, L., Dunn, J. A., Loi, S., Vallier, A., Howe, D. L., Cameron, D. A., . . . Earl, H. M. (2018). Adjuvant trastuzumab duration trials in HER2 positive breast cancer – what results would be practice-changing? Persephone investigator questionnaire prior to primary endpoint results. BMC Cancer.
Citação norma ChicagoHiller, Louise, Janet A. Dunn, Shrushma Loi, Anne-Laure Vallier, Donna L. Howe, David A. Cameron, David Miles, Andrew M. Wardley, e Helena M. Earl. "Adjuvant Trastuzumab Duration Trials in HER2 Positive Breast Cancer – What Results Would Be Practice-changing? Persephone Investigator Questionnaire Prior to Primary Endpoint Results." BMC Cancer 2018.
Citação norma MLAHiller, Louise, et al. "Adjuvant Trastuzumab Duration Trials in HER2 Positive Breast Cancer – What Results Would Be Practice-changing? Persephone Investigator Questionnaire Prior to Primary Endpoint Results." BMC Cancer 2018.